Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Innoviva, Inc. (INVA) since 2005 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Innoviva, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1080014.
Total stock buying since 2005: $366,312,522,213,960.
Total stock sales since 2005: $487,534,090.
Total stock option exercises since 2005: $28,113,268.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 1,618,295 | $28,395,812 | 0 | $0 |
| 2023 | 630,000 | $8,012,816 | 0 | $0 | 0 | $0 |
| 2021 | 20,000 | $264,290 | 32,009,191 | $392,127,262 | 0 | $0 |
| 2020 | 0 | $0 | 2,954 | $43,660 | 0 | $0 |
| 2019 | 17,000 | $252,560 | 0 | $0 | 0 | $0 |
| 2018 | 0 | $0 | 45,580 | $684,706 | 0 | $0 |
| 2017 | 0 | $0 | 58,812 | $762,469 | 0 | $0 |
| 2016 | 0 | $0 | 10,013 | $111,785 | 0 | $0 |
| 2015 | 424,081 | $1,129,205,348,221 | 18,751 | $307,308 | 16,313 | $219,409 |
| 2014 | 1,665,106 | $18,432,850,534,746 | 182,386 | $5,645,964 | 376,064 | $4,199,514 |
| 2013 | 3,504,970 | $344,993,493,913,188 | 553,972 | $19,060,463 | 640,912 | $8,300,131 |
| 2012 | 10,685,150 | $1,756,821,691,496 | 348,417 | $9,411,672 | 384,425 | $3,227,968 |
| 2011 | 471,988 | $11,596,718 | 1,026,134 | $23,587,354 | 989,809 | $8,325,955 |
| 2010 | 5,762,702 | $129,508,015 | 108,805 | $2,038,728 | 131,770 | $1,040,629 |
| 2009 | 0 | $0 | 10,956 | $186,151 | 209,000 | $1,782,724 |
| 2008 | 105,085 | $1,091,910 | 54,676 | $814,364 | 20,000 | $146,900 |
| 2007 | 0 | $0 | 97,648 | $2,586,907 | 64,310 | $471,068 |
| 2006 | 0 | $0 | 41,773 | $1,055,123 | 74,413 | $398,970 |
| 2005 | 0 | $0 | 33,840 | $714,362 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-03 | 0 | $0 | 1,618,295 | $28,395,812 | 0 | $0 |
| 2023-06 | 77,000 | $1,009,862 | 0 | $0 | 0 | $0 |
| 2023-05 | 550,000 | $6,970,350 | 0 | $0 | 0 | $0 |
| 2023-03 | 3,000 | $32,604 | 0 | $0 | 0 | $0 |
| 2021-08 | 0 | $0 | 3,931 | $62,827 | 0 | $0 |
| 2021-05 | 20,000 | $264,290 | 32,005,260 | $392,064,435 | 0 | $0 |
| 2020-02 | 0 | $0 | 2,954 | $43,660 | 0 | $0 |
| 2019-02 | 17,000 | $252,560 | 0 | $0 | 0 | $0 |
| 2018-08 | 0 | $0 | 16,504 | $232,916 | 0 | $0 |
| 2018-05 | 0 | $0 | 13,808 | $198,823 | 0 | $0 |
| 2018-02 | 0 | $0 | 15,268 | $252,967 | 0 | $0 |
| 2017-12 | 0 | $0 | 12,022 | $157,788 | 0 | $0 |
| 2017-11 | 0 | $0 | 33,500 | $444,905 | 0 | $0 |
| 2017-08 | 0 | $0 | 1,825 | $22,265 | 0 | $0 |
| 2017-05 | 0 | $0 | 9,640 | $115,484 | 0 | $0 |
| 2017-02 | 0 | $0 | 1,825 | $22,027 | 0 | $0 |
| 2016-11 | 0 | $0 | 5,500 | $59,724 | 0 | $0 |
| 2016-08 | 0 | $0 | 3,700 | $43,549 | 0 | $0 |
| 2016-05 | 0 | $0 | 813 | $8,512 | 0 | $0 |
| 2015-08 | 245,828 | $856,917,331,181 | 0 | $0 | 0 | $0 |
| 2015-06 | 0 | $0 | 2,438 | $41,080 | 0 | $0 |
| 2015-05 | 85,579 | $117,180,243,856 | 16,313 | $266,228 | 16,313 | $219,409 |
| 2015-03 | 92,674 | $155,107,773,184 | 0 | $0 | 0 | $0 |
| 2014-11 | 832,456 | $10,644,218,756,136 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-03-06 | Sarissa Capital Management Lp | Sale | 1,196,746 | 17.52 | 20,964,596 |
| 2025-03-05 | Sarissa Capital Management Lp | Sale | 270,374 | 17.63 | 4,766,152 |
| 2025-03-04 | Sarissa Capital Management Lp | Sale | 151,175 | 17.63 | 2,665,064 |
| 2023-06-15 | Sarissa Capital Management Lp | Buy | 62,000 | 13.13 | 814,184 |
| 2023-06-06 | Sarissa Capital Management Lp | Buy | 8,000 | 13.05 | 104,384 |
| 2023-06-05 | Sarissa Capital Management Lp | Buy | 7,000 | 13.04 | 91,294 |
| 2023-05-30 | Sarissa Capital Management Lp | Buy | 120,000 | 13.01 | 1,560,600 |
| 2023-05-26 | Sarissa Capital Management Lp | Buy | 30,000 | 13.12 | 393,720 |
| 2023-05-25 | Sarissa Capital Management Lp | Buy | 50,000 | 13.09 | 654,350 |
| 2023-05-18 | Sarissa Capital Management Lp | Buy | 10,000 | 13.05 | 130,540 |
| 2023-05-17 | Sarissa Capital Management Lp | Buy | 50,000 | 13.07 | 653,700 |
| 2023-05-11 | Sarissa Capital Management Lp | Buy | 290,000 | 12.34 | 3,577,440 |
| 2023-03-10 | Raifeld Pavel (Chief Executive Officer) | Buy | 3,000 | 10.87 | 32,604 |
| 2021-08-20 | Zhen Marianne (Chief Accounting Officer) | Sale | 1,129 | 15.89 | 17,939 |
| 2021-08-19 | Zhen Marianne (Chief Accounting Officer) | Sale | 2,802 | 16.02 | 44,888 |
| 2021-05-24 | Bickerstaff George | Buy | 10,000 | 13.46 | 134,620 |
| 2021-05-21 | Bickerstaff George | Buy | 10,000 | 12.97 | 129,670 |
| 2021-05-20 | Glaxosmithkline Plc | Sale | 32,005,260 | 12.25 | 392,064,435 |
| 2020-02-24 | Zhen Marianne (Chief Accounting Officer) | Sale | 2,954 | 14.78 | 43,660 |
| 2019-02-21 | Bickerstaff George | Buy | 10,000 | 14.90 | 148,960 |
| 2019-02-15 | Hulme Geoffrey (Interim PEO) | Buy | 7,000 | 14.80 | 103,600 |
| 2018-08-21 | Witek Theodore J. Jr. (Sr. VP & Chief Scientific Off.) | Sale | 8,504 | 14.12 | 120,076 |
| 2018-08-21 | Abercrombie George B (Sr. VP & Chief Comm. Officer) | Sale | 8,000 | 14.11 | 112,840 |
| 2018-05-21 | Desparbes Eric (SVP and CFO) | Sale | 5,808 | 14.40 | 83,623 |
| 2018-05-21 | Abercrombie George B (Sr. VP & Chief Comm. Officer) | Sale | 8,000 | 14.40 | 115,200 |
| 2018-02-21 | Desparbes Eric (Interim PEO, SVP and CFO) | Sale | 5,378 | 16.52 | 88,823 |
| 2018-02-21 | Witek Theodore J. Jr. (Sr. VP & Chief Scientific Off.) | Sale | 9,890 | 16.60 | 164,144 |
| 2017-12-04 | Aguiar Michael W (President & Chief Exec Officer) | Sale | 12,022 | 13.12 | 157,788 |
| 2017-11-21 | Desparbes Eric (SVP and CFO) | Sale | 13,460 | 13.31 | 179,166 |
| 2017-11-21 | Witek Theodore J. Jr. (Sr. VP & Chief Scientific Off.) | Sale | 13,000 | 13.29 | 172,796 |
| 2017-11-21 | Abercrombie George B (Sr. VP & Chief Comm. Officer) | Sale | 5,215 | 13.26 | 69,145 |
| 2017-11-20 | Desparbes Eric (SVP and CFO) | Sale | 1,825 | 13.04 | 23,798 |
| 2017-08-21 | Desparbes Eric (SVP and CFO) | Sale | 1,825 | 12.20 | 22,265 |
| 2017-05-22 | Desparbes Eric (SVP and CFO) | Sale | 1,825 | 11.85 | 21,626 |
| 2017-05-22 | Witek Theodore J. Jr. (Sr. VP & Chief Scientific Off.) | Sale | 7,815 | 12.01 | 93,858 |
| 2017-02-21 | Desparbes Eric (SVP and CFO) | Sale | 1,825 | 12.07 | 22,027 |
| 2016-11-22 | Witek Theodore L Jr (Sr. VP & Chief Scientific Off.) | Sale | 3,700 | 10.84 | 40,122 |
| 2016-11-21 | Desparbes Eric (SVP and CFO) | Sale | 1,800 | 10.89 | 19,602 |
| 2016-08-22 | Desparbes Eric (SVP and CFO) | Sale | 3,700 | 11.77 | 43,549 |
| 2016-05-18 | Tyree James L | Sale | 813 | 10.47 | 8,512 |
| 2015-08-07 | Glaxosmithkline Plc | Buy | 245,828 | 3,485,841.04 | 856,917,331,181 |
| 2015-06-02 | Tyree James L | Sale | 2,438 | 16.85 | 41,080 |
| 2015-05-27 | Waltrip William H | Sale | 16,313 | 16.32 | 266,228 |
| 2015-05-27 | Waltrip William H | Option Ex | 16,313 | 13.45 | 219,409 |
| 2015-05-11 | Glaxosmithkline Plc | Buy | 85,579 | 1,369,264.00 | 117,180,243,856 |
| 2015-03-02 | Glaxosmithkline Plc | Buy | 92,674 | 1,673,692.44 | 155,107,773,184 |
| 2014-11-04 | Glaxosmithkline Plc | Buy | 832,456 | 12,786,524.16 | 10,644,218,756,136 |
| 2014-08-13 | Lee Junning (Sr. VP, Technical Operations) | Sale | 53,424 | 22.50 | 1,202,040 |
| 2014-08-13 | Lee Junning (Sr. VP, Technical Operations) | Option Ex | 74,441 | 12.41 | 924,185 |
| 2014-08-12 | Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) | Sale | 1,048 | 22.30 | 23,370 |
| 2014-08-11 | Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) | Sale | 27,108 | 22.12 | 599,628 |
| 2014-08-11 | Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) | Option Ex | 33,667 | 14.53 | 489,181 |
| 2014-08-11 | Glaxosmithkline Plc | Buy | 172,651 | 3,912,271.66 | 675,457,614,370 |
| 2014-05-09 | Glaxosmithkline Plc | Buy | 317,770 | 8,544,835.30 | 2,715,292,313,281 |
| 2014-04-17 | Gunderson Robert V Jr | Option Ex | 25,806 | 9.69 | 250,008 |
| 2014-04-07 | Young William D | Option Ex | 25,806 | 9.69 | 250,008 |
| 2014-03-31 | Waltrip William H | Option Ex | 25,806 | 9.69 | 250,008 |
| 2014-03-21 | Levine Arnold J | Option Ex | 25,806 | 9.69 | 250,008 |
| 2014-03-06 | Mammen Mathai (SVP, Research & Early Clin Dev) | Option Ex | 42,153 | 14.20 | 598,572 |
| 2014-03-06 | Whitesides George M | Option Ex | 25,806 | 9.69 | 250,008 |
| 2014-03-03 | Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) | Sale | 65,806 | 36.98 | 2,433,176 |
| 2014-03-03 | Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) | Option Ex | 96,773 | 9.69 | 937,536 |
| 2014-02-14 | Mammen Mathai (SVP, Research & Early Clin Dev) | Sale | 35,000 | 39.65 | 1,387,750 |
| 2014-02-11 | Glaxosmithkline Plc | Buy | 342,229 | 12,850,698.95 | 4,397,881,850,959 |
| 2013-10-29 | Glaxosmithkline Plc | Buy | 130,473 | 4,913,613.18 | 641,093,852,434 |
| 2013-09-12 | Winningham Rick E (Chief Executive Officer) | Sale | 22,353 | 40.03 | 894,790 |
| 2013-08-21 | Mammen Mathai (SVP, Research & Early Clin Dev) | Option Ex | 18,750 | 16.00 | 300,000 |
| 2013-07-30 | Mammen Mathai (SVP, Research & Early Clin Dev) | Sale | 7,000 | 36.51 | 255,570 |
| 2013-07-30 | Glaxosmithkline Plc | Buy | 3,064,407 | 111,850,855.50 | 342,756,544,550,188 |
| 2013-06-07 | Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) | Sale | 31,038 | 35.04 | 1,087,571 |
| 2013-05-29 | Mammen Mathai (SVP, Research & Early Clin Dev) | Option Ex | 11,021 | 7.75 | 85,412 |
| 2013-05-29 | Brinkley David L (Head of Business Dev.) | Sale | 3,808 | 35.01 | 133,318 |
| 2013-05-13 | Brinkley David L (Head of Business Dev.) | Sale | 16,129 | 40.33 | 650,482 |
| 2013-05-13 | Brinkley David L (Head of Business Dev.) | Option Ex | 16,129 | 34.00 | 548,386 |
| 2013-05-03 | Brinkley David L (Head of Business Dev.) | Sale | 16,129 | 34.77 | 560,805 |
| 2013-05-03 | Brinkley David L (Head of Business Dev.) | Option Ex | 16,129 | 29.65 | 478,224 |
| 2013-04-30 | Mammen Mathai (SVP, Research & Early Clin Dev) | Sale | 7,000 | 34.03 | 238,210 |
| 2013-04-30 | Aguiar Michael W (Sr VP, Chief Financial Officer) | Sale | 170,879 | 34.05 | 5,819,284 |
| 2013-04-30 | Aguiar Michael W (Sr VP, Chief Financial Officer) | Option Ex | 170,879 | 17.91 | 3,060,442 |
| 2013-04-30 | Brinkley David L (Head of Business Dev.) | Sale | 17,104 | 34.05 | 582,476 |
| 2013-04-30 | Brinkley David L (Head of Business Dev.) | Option Ex | 8,333 | 6.15 | 51,247 |
| 2013-04-30 | Winningham Rick E (Chief Executive Officer) | Sale | 255,532 | 33.98 | 8,682,977 |
| 2013-04-30 | Winningham Rick E (Chief Executive Officer) | Option Ex | 385,161 | 9.69 | 3,731,439 |
| 2013-04-30 | Glaxosmithkline Plc | Buy | 193,563 | 6,699,215.43 | 1,296,720,236,277 |
| 2013-02-20 | Mammen Mathai (SVP, Research & Early Clin Dev) | Sale | 7,000 | 22.14 | 154,980 |
| 2013-02-15 | Glaxosmithkline Plc | Buy | 116,527 | 2,567,089.81 | 299,135,274,289 |
| 2013-01-11 | Mammen Mathai (SVP, Research & Early Clin Dev) | Option Ex | 14,510 | 3.10 | 44,981 |
| 2012-11-14 | Mammen Mathai (SVP, Research & Early Clin Dev) | Option Ex | 5,161 | 3.10 | 15,999 |
| 2012-11-02 | Mammen Mathai (SVP, Research & Early Clin Dev) | Sale | 7,000 | 21.98 | 153,825 |
| 2012-11-02 | Glaxosmithkline Plc | Buy | 280,348 | 6,265,777.80 | 1,756,598,274,674 |
| 2012-08-27 | Aguiar Michael W (Sr VP, Chief Financial Officer) | Sale | 20,561 | 27.55 | 566,455 |
| 2012-08-24 | Aguiar Michael W (Sr VP, Chief Financial Officer) | Sale | 4,121 | 28.01 | 115,429 |
| 2012-08-24 | Aguiar Michael W (Sr VP, Chief Financial Officer) | Option Ex | 4,121 | 17.91 | 73,807 |
| 2012-08-24 | Brinkley David L (Head of Business Dev.) | Sale | 3,483 | 27.50 | 95,782 |
| 2012-08-13 | Mammen Mathai (SVP, Research & Early Clin Dev) | Sale | 25,000 | 25.91 | 647,875 |
| 2012-08-07 | Aguiar Michael W (Sr VP, Chief Financial Officer) | Sale | 60,000 | 27.04 | 1,622,400 |
| 2012-08-07 | Aguiar Michael W (Sr VP, Chief Financial Officer) | Option Ex | 60,000 | 16.25 | 975,000 |
| 2012-08-03 | Brinkley David L (Head of Business Dev.) | Sale | 123,917 | 27.92 | 3,459,762 |
| 2012-08-03 | Brinkley David L (Head of Business Dev.) | Option Ex | 106,757 | 12.26 | 1,308,840 |
| 2012-08-03 | Winningham Rick E (Chief Executive Officer) | Sale | 75,749 | 27.96 | 2,117,942 |
| 2012-08-03 | Winningham Rick E (Chief Executive Officer) | Option Ex | 145,161 | 3.10 | 449,999 |
| 2012-08-03 | Glaxosmithkline Plc | Buy | 316,334 | 28.21 | 8,923,782 |
| 2012-05-29 | Aguiar Michael W (Sr VP, Chief Financial Officer) | Sale | 20,000 | 22.29 | 445,800 |
| 2012-05-16 | Glaxosmithkline Plc | Buy | 10,000,000 | 21.29 | 212,890,000 |
| 2012-05-04 | Winningham Rick E (Chief Executive Officer) | Option Ex | 63,225 | 6.39 | 404,323 |
| 2012-05-01 | Drazan Jeffrey M | Sale | 8,586 | 21.71 | 186,402 |
| 2012-02-14 | Glaxosmithkline Plc (10% Owner) | Buy | 88,468 | 18.12 | 1,603,040 |
| 2011-12-09 | Aguiar Michael W (Sr VP, Chief Financial Officer) | Sale | 10,000 | 21.86 | 218,600 |
| 2011-11-28 | Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) | Sale | 20,000 | 21.00 | 420,000 |
| 2011-11-28 | Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) | Option Ex | 30,205 | 8.53 | 257,648 |
| 2011-11-28 | Drazan Jeffrey M | Sale | 4,293 | 21.00 | 90,153 |
| 2011-11-01 | Glaxosmithkline Plc (10% Owner) | Buy | 58,411 | 22.23 | 1,298,476 |
| 2011-09-01 | Mammen Mathai (SVP, Research & Early Clin Dev) | Option Ex | 3,225 | 8.53 | 27,493 |
| 2011-06-14 | Aguiar Michael W (Sr VP, Chief Financial Officer) | Sale | 14,225 | 22.94 | 326,321 |
| 2011-06-07 | Drazan Jeffrey M (Director) | Sale | 31,907 | 23.29 | 743,114 |
| 2011-06-06 | Drazan Jeffrey M (Director) | Sale | 37,344 | 23.08 | 861,899 |
| 2011-05-31 | Brinkley David L (Head of Business Dev.) | Sale | 51,500 | 25.65 | 1,320,975 |
| 2011-05-31 | Brinkley David L (Head of Business Dev.) | Option Ex | 45,441 | 14.03 | 637,537 |
| 2011-05-27 | Brinkley David L (Head of Business Dev.) | Sale | 57,812 | 25.31 | 1,463,221 |
| 2011-05-27 | Brinkley David L (Head of Business Dev.) | Option Ex | 57,812 | 5.30 | 306,230 |
| 2011-05-11 | Winningham Rick E (Chief Executive Officer) | Sale | 73,100 | 26.28 | 1,921,068 |
| 2011-05-10 | Winningham Rick E (Chief Executive Officer) | Sale | 54,646 | 26.41 | 1,443,200 |
| 2011-05-03 | Glaxosmithkline Plc | Buy | 261,299 | 25.60 | 6,689,254 |
| 2011-03-16 | Brinkley David L (Head of Business Dev.) | Sale | 2,100 | 22.02 | 46,242 |
| 2011-03-16 | Brinkley David L (Head of Business Dev.) | Option Ex | 2,100 | 3.10 | 6,510 |
| 2011-03-15 | Brinkley David L (Head of Business Dev.) | Sale | 45,492 | 22.08 | 1,004,463 |
| 2011-03-15 | Brinkley David L (Head of Business Dev.) | Option Ex | 45,492 | 4.91 | 223,365 |
| 2011-03-11 | Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) | Sale | 26,689 | 22.75 | 607,308 |
| 2011-03-07 | Young William D | Sale | 5,376 | 22.31 | 119,938 |
| 2011-03-07 | Young William D | Option Ex | 10,752 | 8.53 | 91,660 |
| 2011-03-01 | Winningham Rick E (Chief Executive Officer) | Sale | 63,873 | 22.53 | 1,439,058 |
| 2011-02-28 | Winningham Rick E (Chief Executive Officer) | Sale | 67,000 | 22.99 | 1,540,330 |
| 2011-02-28 | Winningham Rick E (Chief Executive Officer) | Option Ex | 101,752 | 8.53 | 867,435 |
| 2011-02-25 | Winningham Rick E (Chief Executive Officer) | Sale | 92,200 | 22.48 | 2,072,656 |
| 2011-02-25 | Winningham Rick E (Chief Executive Officer) | Option Ex | 135,850 | 8.53 | 1,158,121 |
| 2011-02-24 | Winningham Rick E (Chief Executive Officer) | Sale | 93,100 | 21.45 | 1,996,995 |
| 2011-02-24 | Winningham Rick E (Chief Executive Officer) | Option Ex | 135,950 | 8.53 | 1,158,973 |
| 2011-02-23 | Winningham Rick E (Chief Executive Officer) | Sale | 97,600 | 21.14 | 2,063,264 |
| 2011-02-23 | Winningham Rick E (Chief Executive Officer) | Option Ex | 142,500 | 8.53 | 1,214,812 |
| 2011-02-22 | Winningham Rick E (Chief Executive Officer) | Sale | 168,800 | 21.79 | 3,678,152 |
| 2011-02-22 | Winningham Rick E (Chief Executive Officer) | Option Ex | 258,140 | 8.53 | 2,200,643 |
| 2011-02-18 | Mammen Mathai (SVP, Research & Early Clin Dev) | Sale | 3,701 | 23.12 | 85,567 |
| 2011-02-18 | Young William D | Sale | 5,376 | 23.22 | 124,830 |
| 2011-02-18 | Young William D | Option Ex | 10,752 | 8.53 | 91,660 |
| 2011-02-18 | Glaxosmithkline Plc | Buy | 152,278 | 23.70 | 3,608,988 |
| 2011-01-28 | Mammen Mathai (SVP, Research & Early Clin Dev) | Option Ex | 9,838 | 8.53 | 83,868 |
| 2010-12-10 | Young William D | Sale | 5,377 | 26.64 | 143,243 |
| 2010-12-10 | Young William D | Option Ex | 10,754 | 8.53 | 91,677 |
| 2010-12-03 | Aguiar Michael W (Sr VP, Chief Financial Officer) | Sale | 10,000 | 26.51 | 265,100 |
| 2010-12-01 | Brinkley David L (Head of Business Dev.) | Sale | 20,000 | 25.07 | 501,400 |
| 2010-12-01 | Brinkley David L (Head of Business Dev.) | Option Ex | 15,275 | 3.10 | 47,352 |
| 2010-11-29 | Glaxosmithkline Plc (10% Owner) | Buy | 5,750,000 | 22.50 | 129,375,000 |
| 2010-09-14 | Brinkley David L (Head of Business Dev.) | Sale | 1,980 | 15.12 | 29,937 |
| 2010-09-07 | Mammen Mathai (SVP, Research & Early Clin Dev) | Option Ex | 6,451 | 8.53 | 54,994 |
| 2010-09-01 | Mammen Mathai (SVP, Research & Early Clin Dev) | Sale | 4,416 | 12.84 | 56,701 |
| 2010-06-15 | Brinkley David L (Head of Business Dev.) | Sale | 33,516 | 15.45 | 517,822 |
| 2010-06-15 | Brinkley David L (Head of Business Dev.) | Option Ex | 33,516 | 8.53 | 285,723 |
| 2010-06-14 | Brinkley David L (Head of Business Dev.) | Sale | 33,516 | 15.65 | 524,525 |
| 2010-06-14 | Brinkley David L (Head of Business Dev.) | Option Ex | 33,516 | 8.53 | 285,723 |
| 2010-02-25 | Blum Leonard M (Sr VP, Chief Comm. Officer) | Buy | 677 | 10.33 | 6,993 |
| 2010-02-25 | Waltrip William H | Option Ex | 32,258 | 8.53 | 275,160 |
| 2010-02-24 | Blum Leonard M (Sr VP, Chief Comm. Officer) | Buy | 12,025 | 10.48 | 126,022 |
| 2009-12-23 | Vagelos P Roy | Option Ex | 200,000 | 8.53 | 1,705,999 |
| 2009-12-16 | Brinkley David L (Head of Business Dev.) | Sale | 1,956 | 13.01 | 25,447 |
| 2009-09-15 | Brinkley David L (Head of Business Dev.) | Sale | 9,000 | 17.86 | 160,704 |
| 2009-09-15 | Brinkley David L (Head of Business Dev.) | Option Ex | 9,000 | 8.53 | 76,725 |
| 2008-07-30 | Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) | Sale | 34,676 | 15.97 | 553,671 |
| 2008-06-04 | Kitt Michael (Sr. Vice President Development) | Sale | 15,000 | 13.04 | 195,570 |
| 2008-06-04 | Kitt Michael (Sr. Vice President Development) | Option Ex | 15,000 | 8.53 | 127,875 |
| 2008-06-03 | Kitt Michael (Sr. Vice President Development) | Sale | 1,300 | 13.06 | 16,975 |
| 2008-06-03 | Kitt Michael (Sr. Vice President Development) | Option Ex | 1,300 | 5.81 | 7,555 |
| 2008-06-02 | Kitt Michael (Sr. Vice President Development) | Sale | 3,700 | 13.01 | 48,148 |
| 2008-06-02 | Kitt Michael (Sr. Vice President Development) | Option Ex | 3,700 | 3.10 | 11,470 |
| 2008-03-14 | Vagelos P Roy | Buy | 25,000 | 10.22 | 255,862 |
| 2008-03-13 | Vagelos P Roy | Buy | 24,000 | 10.52 | 252,360 |
| 2008-03-11 | Winningham Rick E (Chief Executive Officer) | Buy | 20,000 | 10.44 | 208,860 |
| 2008-03-10 | Blum Leonard M (Sr VP, Chief Comm. Officer) | Buy | 28,385 | 10.45 | 296,481 |
| 2007-12-14 | Brinkley David L (Sr. VP Commercial Development) | Sale | 4,439 | 22.64 | 100,498 |
| 2007-12-10 | Humphrey Patrick Pa (Executive VP Research) | Option Ex | 54,310 | 7.10 | 385,818 |
| 2007-10-31 | Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) | Sale | 25,000 | 25.00 | 625,000 |
| 2007-09-14 | Brinkley David L (Sr. VP Commercial Development) | Sale | 3,623 | 27.64 | 100,154 |
| 2007-08-23 | Kitt Michael (Sr. Vice President Development) | Sale | 10,000 | 30.01 | 300,100 |
| 2007-08-23 | Kitt Michael (Sr. Vice President Development) | Option Ex | 10,000 | 8.53 | 85,250 |
| 2007-08-01 | Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) | Sale | 25,000 | 26.07 | 650,153 |
| 2007-06-15 | Brinkley David L (Sr. VP Commercial Development) | Sale | 2,986 | 33.59 | 100,287 |
| 2007-02-28 | Brinkley David L (Sr. VP Commercial Development) | Sale | 3,100 | 31.94 | 99,014 |
| 2006-06-29 | Kitt Michael (Sr. Vice President Development) | Option Ex | 8,008 | 3.10 | 24,824 |
| 2006-06-09 | Kitt Michael (Sr. Vice President Development) | Sale | 16,129 | 24.15 | 389,614 |
| 2006-06-09 | Kitt Michael (Sr. Vice President Development) | Option Ex | 14,999 | 3.10 | 46,496 |
| 2006-05-03 | Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) | Option Ex | 40,761 | 5.81 | 236,902 |
| 2006-05-02 | Loewenthal Ronn | Sale | 10,645 | 28.47 | 303,020 |
| 2006-05-02 | Loewenthal Ronn | Option Ex | 10,645 | 8.53 | 90,748 |
| 2005-12-13 | Baker Julian | Sale | 33,840 | 21.11 | 714,362 |
Insider trading activities including stock purchases, stock sales, and option exercises of INVA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Innoviva, Inc. (symbol INVA, CIK number 1080014) see the Securities and Exchange Commission (SEC) website.